NCT06517667View on ClinicalTrials.gov

Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

June 1, 2024

Conditions
Dry Eye
Interventions
DRUG

Icross tear substitute

Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.

DRUG

Hyabak tear substitute

Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.

Trial Locations (1)

30009

Novovision ophthalmologic clinic, Murcia

All Listed Sponsors
lead

University of Seville

OTHER

NCT06517667 - Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye | Biotech Hunter | Biotech Hunter